BLU:NSD-BELLUS Health Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.96

Change

-0.69 (-6.48)%

Market Cap

USD 0.60B

Volume

0.16M

Average Target Price

N/A
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered development stage programs, including KIACTA for the treatment of sarcoidosis; AMO-01 for treatment of Phelan McDermid syndrome; and ALZ-801 for APOE4 homozygous Alzheimer's disease. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-02-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-9.28 (-3.77%)

USD61.45B 52.55 46.39
REGN Regeneron Pharmaceuticals, Inc

+22.23 (+5.51%)

USD44.35B 21.84 16.87
ALXN Alexion Pharmaceuticals, Inc

-4.12 (-3.99%)

USD21.92B 9.25 9.18
SGEN Seattle Genetics, Inc

-1.00 (-0.85%)

USD19.94B N/A -99.92
GLPG Galapagos NV

-28.49 (-10.40%)

USD17.88B 72.40 0.00
INCY Incyte Corporation

-2.02 (-2.50%)

USD17.10B 38.47 32.51
BMRN BioMarin Pharmaceutical Inc

-2.16 (-2.27%)

USD16.71B N/A -338.24
GMAB Genmab A/S

-0.56 (-2.22%)

USD16.13B N/A -0.00
ALNY Alnylam Pharmaceuticals, Inc

-8.74 (-6.67%)

USD14.75B N/A -14.66
BGNE BeiGene, Ltd

-5.58 (-3.29%)

USD13.15B N/A -11.15

ETFs Containing BLU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 31.05% 84% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.05% 84% B 92% A-
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.60B 69% D+ 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -58.75 92% A- 93% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -32.27% 80% B- 29% F
Return on Invested Capital -25.77% 70% C- 24% F
Return on Assets -19.70% 72% C- 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.65 80% B- 83% B
Short Percent N/A N/A N/A N/A N/A
Beta 0.88 75% C 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

STA Verdict Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.